Alliancebernstein L.P. Has $25.28 Million Position in Dianthus Therapeutics, Inc. (NASDAQ:DNTH)

Alliancebernstein L.P. lifted its stake in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 13.4% in the 4th quarter, Holdings Channel reports. The institutional investor owned 1,159,776 shares of the company’s stock after acquiring an additional 136,633 shares during the period. Alliancebernstein L.P.’s holdings in Dianthus Therapeutics were worth $25,283,000 as of its most recent filing with the SEC.

A number of other institutional investors have also added to or reduced their stakes in DNTH. State Street Corp increased its holdings in Dianthus Therapeutics by 101.4% in the 3rd quarter. State Street Corp now owns 821,131 shares of the company’s stock valued at $22,483,000 after buying an additional 413,425 shares during the period. Charles Schwab Investment Management Inc. boosted its position in shares of Dianthus Therapeutics by 0.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 167,021 shares of the company’s stock valued at $3,641,000 after acquiring an additional 1,092 shares in the last quarter. Wellington Management Group LLP increased its stake in Dianthus Therapeutics by 12.2% in the fourth quarter. Wellington Management Group LLP now owns 60,337 shares of the company’s stock valued at $1,315,000 after acquiring an additional 6,552 shares during the period. American Century Companies Inc. raised its position in Dianthus Therapeutics by 3.8% in the fourth quarter. American Century Companies Inc. now owns 43,996 shares of the company’s stock worth $959,000 after purchasing an additional 1,629 shares in the last quarter. Finally, Barclays PLC lifted its stake in Dianthus Therapeutics by 390.5% during the third quarter. Barclays PLC now owns 41,684 shares of the company’s stock worth $1,141,000 after purchasing an additional 33,185 shares during the period. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ:DNTH opened at $15.61 on Tuesday. The business has a fifty day moving average of $21.37 and a 200-day moving average of $23.81. Dianthus Therapeutics, Inc. has a twelve month low of $14.78 and a twelve month high of $32.27. The firm has a market cap of $501.47 million, a PE ratio of -6.24 and a beta of 1.62.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.85) by $0.04. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. The firm had revenue of $1.33 million during the quarter, compared to analysts’ expectations of $1.40 million. On average, analysts anticipate that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on DNTH shares. Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a research note on Thursday, December 12th. Wedbush reiterated an “outperform” rating and set a $36.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. Guggenheim restated a “buy” rating and issued a $84.00 target price on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. TD Cowen started coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They issued a “buy” rating on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Seven investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Dianthus Therapeutics has an average rating of “Buy” and a consensus price target of $54.33.

Dianthus Therapeutics Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.